Cost-efficiency and expanded access modeling of conversion to biosimilar bevacizumab in metastatic colorectal and non-squamous non-small cell lung cancer in Medicare.
Saved in:
| Title: | Cost-efficiency and expanded access modeling of conversion to biosimilar bevacizumab in metastatic colorectal and non-squamous non-small cell lung cancer in Medicare. |
|---|---|
| Authors: | Roth JA; Pfizer, New York, NY, USA.; School of Pharmacy, University of Washington, Seattle, WA, USA., Kratochvil D; OPEN Health, Bethesda, MD, USA., Dorman S; Pfizer, New York, NY, USA., Bernauer M; OPEN Health, Bethesda, MD, USA. |
| Source: | Journal of medical economics [J Med Econ] 2025 Dec; Vol. 28 (1), pp. 378-386. Date of Electronic Publication: 2025 Mar 11. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 9892255 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1941-837X (Electronic) Linking ISSN: 13696998 NLM ISO Abbreviation: J Med Econ Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1941-837X |
|---|---|
| DOI: | 10.1080/13696998.2025.2474884 |
